Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above (FAST)
A Phase IV, Open Label, Clinical Trial to Assess Safety and Efficacy of Fexofenadine HCL + Pseudoephedrine HCL Fixed Dose Combination in Indian Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above (FAST Trial)
Sponsor: Sanofi
A PHASE4 clinical study on Rhinitis Allergic, this trial is completed. The trial is conducted by Sanofi and has accumulated 8 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE4
Status: Not Yet Recruiting → Completed
-
Jun 2025 — Feb 2026 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE4
-
Sep 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE4
▶ Show 3 earlier versions
-
Aug 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE4
-
May 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE4
-
Mar 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .